Application of targeted therapy combined with immune checkpoint inhibitors in the treatment of HER2 positive advanced gastric cancer

doi:10.3760/cma.j.cn371439-20230428-00120

Abstract

Abstract:

Human epidermal growth factor receptor 2 （HER2）， programmed death-1 and programmed death-ligand 1 are related to the proliferation， invasion and metastasis of various tumor cells. A variety of antibodies and small molecule drugs targeting HER2 have achieved considerable results in clinical practice. Immune checkpoint inhibitors targeting programmed death-1 and programmed death-ligand 1 have significant effects in clinical application. In the KEYNOTE-811 trial， the combination of immune checkpoint inhibitors and targeted therapy has achieved encouraging results in HER2-positive advanced gastric cancer.

Key words: Stomach neoplasms, Receptor， erbB-2, Immune checkpoint inhibitors

Yu Xiaopeng, Feng Qingqing, Zhao Wenfei, Zhao Wenwen, Wei Hongmei. Application of targeted therapy combined with immune checkpoint inhibitors in the treatment of HER2 positive advanced gastric cancer[J]. Journal of International Oncology, 2023, 50(10): 631-635.

References 29

[1]	中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)胃癌诊疗指南2022[M]. 北京: 人民卫生出版社, 2022.
[2]	Chaganty BKR, Qiu S, Gest A, et al. Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion[J]. Cancer Lett, 2018, 430: 47-56. DOI: 10.1016/j.canlet.2018.05.009. pmid: 29746929
[3]	Voutsadakis IA. HER2 in stemness and epithelial-mesenchymal plasticity of breast cancer[J]. Clin Transl Oncol, 2019, 21(5): 539-555. DOI: 10.1007/s12094-018-1961-x. pmid: 30306401
[4]	Yamashita K, Iwatsuki M, Yasuda-Yoshihara N, et al. Trastuzumab upregulates programmed death ligand-1 expression through interaction with NK cells in gastric cancer[J]. Br J Cancer, 2021, 124(3): 595-603. DOI: 10.1038/s41416-020-01138-3.
[5]	Iwata TN, Ishii C, Ishida S, et al. A HER2-targeting antibody-drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model[J]. Mol Cancer Ther, 2018, 17(7): 1494-1503. DOI: 10.1158/1535-7163.MCT-17-0749. pmid: 29703841
[6]	Mandikian D, Takahashi N, Lo AA, et al. Relative target affinities of T-cell-dependent bispecific antibodies determine biodistribution in a solid tumor mouse model[J]. Mol Cancer Ther, 2018, 17(4): 776-785. DOI: 10.1158/1535-7163.MCT-17-0657. pmid: 29339550
[7]	Janjigian YY, Kawazoe A, Yañez P, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer[J]. Nature, 2021, 600(7890): 727-730. DOI: 10.1038/s41586-021-04161-3.
[8]	Subramanian J, Katta A, Masood A, et al. Emergence of ERBB2 mutation as a biomarker and an actionable target in solid cancers[J]. Oncologist, 2019, 24(12): e1303-e1314. DOI: 10.1634/theoncologist.2018-0845.
[9]	Patsoukis N, Wang Q, Strauss L, et al. Revisiting the PD-1 pathway[J]. Sci Adv, 2020, 6(38): eabd2712. DOI: 10.1126/sciadv.abd2712.
[10]	Böger C, Behrens HM, Mathiak M, et al. PD-L1 is an independent prognostic predictor in gastric cancer of western patients[J]. Oncotarget, 2016, 7(17): 24269-24283. DOI: 10.18632/oncotarget.8169. pmid: 27009855
[11]	赵丽丽, 赵文文, 冯青青, 等. 沉默PD-L1表达对胃癌细胞生物学行为的影响[J]. 国际肿瘤学杂志, 2021, 48(12): 705-710. DOI: 10.3760/cma.j.cn371439-20210813-00140.
[12]	Wang L, Zhang Q, Ni S, et al. Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status[J]. Cancer Med, 2018, 7(6): 2612-2620. DOI: 10.1002/cam4.1502.
[13]	Lian J, Zhang G, Zhang Y, et al. PD-L1 and HER2 expression in gastric adenocarcinoma and their prognostic significance[J]. Dig Liver Dis, 2022, 54(10): 1419-1427. DOI: 10.1016/j.dld.2022.01.128.
[14]	Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial[J]. JAMA Oncol, 2018, 4(5): e180013.DOI: 10.1001/jamaoncol.2018.0013.
[15]	Shitara K, Özgüroğlu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial[J]. Lancet, 2018, 392(10142): 123-133. DOI: 10.1016/S0140-6736(18)31257-1. pmid: 29880231
[16]	Shitara K, Van Cutsem E, Bang YJ, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial[J]. JAMA Oncol, 2020, 6(10): 1571-1580. DOI: 10.1001/jamaoncol.2020.3370.
[17]	Loi S, Giobbie-Hurder A, Gombos A, et al. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial[J]. Lancet Oncol, 2019, 20(3): 371-382. DOI: 10.1016/S1470-2045(18)30812-X. pmid: 30765258
[18]	Rha SY, Lee CK, Kim HS, et al. Targeting HER2 in combination with anti-PD-1 and chemotherapy confers a significant tumor shrinkage of gastric cancer: a multi-institutional phase Ⅰb/Ⅱ trial of first-line triplet regimen (pembrolizumab, trastuzumab, chemotherapy) for HER2-positive advanced gastric cancer (AGC)[J]. J Clin Oncol, 2020, 38(38(15_suppl): 3081. DOI: 10.1200/JCO.2020.
[19]	Lee CK, Rha SY, Kim HS, et al. A single arm phase Ⅰb/Ⅱ trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer[J]. Nat Commun, 2022, 13(1): 6002. DOI: 10.1038/s41467-022-33267-z.
[20]	Wang KX, Cui TY, Yang XD, et al. Study on efficacy and safety of low-dose apatinib combined with camrelizumab and SOX regimen as first-line treatment of locally advanced and unresectable gastric/gastroesophageal junction cancer: a protocol for an open-label, dose escalation and extension phaseⅠb clinical trial[J]. Onco Targets Ther, 2021, 14: 4859-4865. DOI: 10.2147/OTT.S316288.
[21]	National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer (version 1.2023)[EB/OL]. [2023-04-10]. https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf.
[22]	Huang J, Mo H, Zhang W, et al. Promising efficacy of SHR-1210, a novel anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China[J]. Cancer, 2019, 125(5): 742-749. DOI: 10.1002/cncr.31855. pmid: 30508306
[23]	Xu M, Meng X, Lu Y, et al. Efficacy and safety of camrelizumab in combination with trastuzumab and chemotherapy as the first-line treatment for patients with HER2-positive advanced gastric cancer[J]. J Gastrointest Oncol, 2022, 13(2): 548-558. DOI: 10.21037/jgo-21-897. pmid: 35557572
[24]	张鑫鑫, 李帅, 吴晨, 等. HER-2阳性晚期胃癌免疫治疗临床分析[J]. 中国肿瘤临床, 2022, 49(16): 840-845. DOI: 10.12354/j.issn.1000-8179.2022.20220156.
[25]	Markham A. Margetuximab: first approval[J]. Drugs, 2021, 81(5): 599-604. DOI: 10.1007/s40265-021-01485-2. pmid: 33761116
[26]	Catenacci DVT, Kang YK, Park H, et al. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial[J]. Lancet Oncol, 2020, 21(8): 1066-1076. DOI: 10.1016/S1470-2045(20)30326-0.
[27]	Stein A, Paschold L, Tintelnot J, et al. Efficacy of ipilimumab vs FOLFOX in combination with nivolumab and trastuzumab in patients with previously untreated ERBB2-positive esophagogastric adenocarcinoma: the AIO INTEGA randomized clinical trial[J]. JAMA Oncol, 2022, 8(8): 1150-1158. DOI: 10.1001/jamaoncol.2022.2228. pmid: 35737383
[28]	Catenacci DV, Rosales M, Chung HC, et al. MAHOGANY: margetuximab combination in HER2⁺ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma[J]. Future Oncol, 2021, 17(10): 1155-1164. DOI: 10.2217/fon-2020-1007. pmid: 33263418
[29]	Catenacci DVT, Kang YK, Yoon HH, et al. Margetuximab with retifanlimab as first-line therapy in HER2⁺/PD-L1⁺ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A[J]. ESMO Open, 2022, 7(5): 100563. DOI: 10.1016/j.esmoop.2022.100563.